Last Updated : June 24, 2024
Details
Generic Name:
clascoterone
Project Status:
Pending
Therapeutic Area:
Acne vulgaris
Manufacturer:
Sun Pharma Canada Inc.
Call for patient/clinician input open:
Brand Name:
Winlevi
Project Line:
Reimbursement Review
Project Number:
SR0863-000
Call for patient/clinician input closed:
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For the first-line prescription topical treatment of moderate and severe acne vulgaris in patients 12 years of age and older.
Submission Type:
Initial
Fee Schedule:
Pending
Indications:
For the topical treatment of acne vulgaris in patients 12 years of age and older.
Anticipated Date:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
Last Updated : June 24, 2024